Company news

Agenus Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Agenus Corporate Update and First Quarter 2021 Financial Report

May 5, 2021

Agenus to Provide Corporate Update and First Quarter 2021 Financial Report

April 21, 2021

Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

April 18, 2021

Agenus Doses First Cancer Patient with iNKT Cell Therapy

April 13, 2021

Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report

March 14, 2021

Agenus Announces Agenus Insights - Virtual R&D Miniseries

February 8, 2021

Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

February 3, 2021

Completion of Balstilimab BLA Filing Extended To 1H2021

December 2, 2020

Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab

November 30, 2020

An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2

November 9, 2020

Agenus Doses First COVID-19 Patient with iNKT Cell Therapy

November 1, 2020

Susan Hirsch Joins Agenus’ Board of Directors

October 12, 2020

Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer

September 17, 2020

Paul Clark Joins Agenus Board of Directors

August 30, 2020

Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer

August 25, 2020

Agenus Provides R&D Update & Second Quarter Financial Report

August 5, 2020

Agenus First Quarter Results and Update

May 6, 2020

Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast

April 27, 2020

Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer

April 6, 2020

Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast

March 2, 2020

Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer

February 19, 2020

Agenus Announces Investor Day on February 20, 2020

February 5, 2020

Agenus Commences Phase 1 trial with AGEN1223

January 7, 2020

Agenus to Host R&D Day November 15, 2019

November 11, 2019

Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers

November 10, 2019

Agenus Provides Corporate Update with Third Quarter 2019 Financial Results

November 3, 2019

Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast

October 30, 2019

Agenus Milestone Triggers $7.5M Payment

August 7, 2019

Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast

August 5, 2019

Agenus Appoints Don Vidic as Vice President and Head of Commercial

July 17, 2019

Agenus to Host Annual Meeting of Stockholders

June 12, 2019

Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody

April 1, 2019

← Newer news releases

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.